Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →GSK has taken full control of the mRNA vaccine programs it had been jointly developing with CureVac, paying €400 million upfront and potentially up to…
GSK is taking full control of its mRNA vaccine partnership with CureVac, restructuring a 2020 collaboration into a licensing deal worth up to €1.45 billion.…
BioNTech closed acquisition of CureVac N.V. on 18 Dec 2025 (~86.75% / 195,341,219 shares tendered); compulsory acquisition of remaining shares expected Jan…
Source summaries from our enrichment pipeline; follow links for originals.
All 13 sources with sentiment breakdown →
GSK and CureVac restructured their existing 2020 mRNA collaboration into a new licensing agreement. CureVac receives €400M (~$434M) upfront and up to €1.05B in development, regulatory and sales milestones plus tiered royalties. GSK gains full global rights to develop, manufacture and commercialize mRNA vaccines for seasonal flu, COVID-19, and avian flu currently in Phase 1/2 development.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| GSK plc / CureVac N.V. (this deal) | 2024 | $1.6B | — |
| GSK plc / SmithKline Beecham | 2000 | $12.0B | 79 |
| GSK plc / Pfizer Inc. | 2018 | $0.0M | 77 |
| GSK plc / Novartis AG | 2014 | $16.0B | 76 |
| GSK plc / Hansoh Pharmaceutical Group Co. Ltd. | 2023 | $1.7B | 74 |
| GSK plc / Nuvalent, Inc. | 2026 | $10.6B | 70 |
| GSK plc / Sierra Oncology Inc. | 2022 | $1.9B | 70 |
← Browse all deals · How we score deals
More: 2024 deals · GSK plc deals · Infectious Disease deals